EE20/DRSP(BAY86-5300)

Phase 3Small molecule

Bayer

EE20/DRSP(BAY86-5300) is one of 67 small molecule programs targeting Dysmenorrhea. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

DysmenorrheaActive, not recruiting

EndometriosisActive, not recruiting

DysmenorrheaPhase 3

Active, not recruiting

EndometriosisPhase 3

Active, not recruiting

Competition

Competitive Landscape

199 competitors in Endometriosis

#DrugCompanyPhaseTrials

Lupron

AbbVie

Phase 3

1 2

Leuprorelin

Takeda

Phase 3

8 3

Orgovyx

Sumitomo Pharma America, Inc.

Phase 3

3 4

Trental

VValidus Pharmaceuticals

Phase 3

1 5

Firmagon

Ferring

Phase 3

1 6

Estradiol/norethindrone Acetate

AbbVie

Phase 3

5 7

Esketamine Hydrochloride

TThe Second Hospital of Anhui Medical University

Phase 3

1 8

Indole-3-Carbinol

UUniversity of Kansas Medical Center

Phase 3

1 9

Add-Back

KKissei Pharmaceutical Co., Ltd.

Phase 3

4 10

Visanne

Bayer

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Dysmenorrhea2 trials

To Investigate Efficacy of YAZ in the Treatment of Dysmenorrhea

Withdrawn· Bayer logo

Bayer·Phase 3·NCT02617537

Comparative Study of BAY86-5300 With a Flexible Extended Regimen for Dysmenorrhea

Completed· Bayer logo

Bayer·Phase 3·NCT01892904·216 enrolled

Endometriosis1 trial

Comparative Study of BAY86-5300 With an Extended Flexible Regimen for Endometriosis

Completed· Bayer logo

Bayer·Phase 3·NCT01697111·312 enrolled

Oral1 trial

Clinical Study of a Conventional and Flexible Extended Oral Contraceptive of EE/DRSP With or Without Metafolin in Latin America

Withdrawn· Bayer logo

Bayer·Phase 3·NCT01331655

Efficacy and Safety1 trial

Efficacy and Safety of Two Flexible Extended Regimens of BAY86-5300 (SH T00186D) in Comparison With the Conventional Regimen of YAZ

Completed· Bayer logo

Bayer·Phase 3·NCT00567164·1,887 enrolled

MDD1 trial

YAZ Premenstrual Dysphoric Disorder (PMDD) in China

Completed· Bayer logo

Bayer·Phase 3·NCT00824187·187 enrolled

3 more indications

Efficacy1 trial

YAZ Post Authorization Safety Study (PASS)/Post Authorization Efficacy Study (PAES) in China

Completed· Bayer logo

Bayer·Phase 4·NCT02710708·1,921 enrolled

Withdrawal1 trial

Comparative Trial in Hormone Withdrawal Associated Symptoms

Completed· Bayer logo

Bayer·Phase 3·NCT01076582·592 enrolled

Unspecified2 trials

Regulatory Post Marketing Surveillance Study on YAZ

Completed· Bayer logo

Bayer··NCT00998257·770 enrolled

YAZ Post-marketing Surveillance in Japan

Completed· Bayer logo

Bayer··NCT01375998·3,273 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for EE20/DRSP(BAY86-5300). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — EE20/DRSP(BAY86-5300) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for EE20/DRSP(BAY86-5300). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bayer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Bayer

EE20/DRSP(BAY86-5300)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Dysmenorrhea2 trials

Endometriosis1 trial

Oral1 trial

Efficacy and Safety1 trial

MDD1 trial

Efficacy1 trial

Withdrawal1 trial

Unspecified2 trials

References

Drug Info

Quick Facts

Related News